Oslo, 27 February 2026: Reference is made to the stock exchange announcements
published on 5 February 2026 by EXACT Therapeutics AS (the "Company", Euronext
Growth ticker: EXTX), a clinical-stage precision medicine company, regarding the
exercise of warrants issued in conjunction with the private placement completed
in December 2024, representing 75% of the total warrants issued and
corresponding to gross proceeds of NOK 46 million. As previously stated, the
remaining warrant holders could exercise their warrants within 26 February 2026.
The Company is pleased to confirm that after closing of the warrants period, it
has received exercise notices from a total of 96% of the warrants issued,
corresponding to gross proceeds of NOK 59.4 million.
The Company will call for an extraordinary general meeting to ensure that the
relevant number of new shares are issued.
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases. EXACT
Therapeutics' shares are traded on Euronext Growth Oslo (EXTX). Further
information may be found here:www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com